FGFR1 Amplification in Metastatic Squamous Cell Carcinoma of the Head and Neck – A Potential Target for a Rational Therapy?
Friederike Goeke, Alina Franzen, Roopika Mennon, Robert Kirsten, Diana Boehm, Wenzel Vogel, Friedrich Bootz, Andreas Schroeck, Sven Perner. University Hospital Bonn, Bonn, Germany
Background: Currently, patients with FGFR1 amplified squamous cell lung cancers (L-SCC) are treated in phase I clinical trials using small molecule inhibitors. Of interest, SCC of the lung share common molecular alterations with squamous cell head and neck cancers (HN-SCC). Aim of our study is to assess if HN-SCCs also harbor FGFR1 amplifications.
Design: We put together a cohort of 227 patients suffering from HN-SCC, with 97 of these suffering from metastatic disease. Primary tumors and, where available, metastatic tumors were assessed for FGFR1 copy number status using fluorescence in-situ hybridization (FISH).
Results: 20,3% of primary HN-SCC displayed FGFR1 amplifications. Of interest, almost all metastatic tumor samples revealed a FGFR1 amplification if the corresponding primary tumor harbored the amplification.
Conclusions: FGFR1 amplification frequently occurs in primary and metastatic HN-SCC and proves as a potential target for small molecule therapy in non-operable or metastatic disease. Further functional studies and subsequent clinical trials are needed for further validation of our findings.
Category: Head & Neck
Wednesday, March 21, 2012 9:30 AM
Poster Session V # 185, Wednesday Morning